Hidalgo-Curtis, C., Chase, A. J., Drachenberg, M., Roberts, M. W., Mould, S. J., Finkelstein, J. Z., Oscier, D. G., Cross, N. C.P. and Grand, F. H., 2008. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteinsSFPQ (PSF) andCPSF6 toABL andFGFR1. Genes Chromosomes and Cancer, 47 (5), pp. 379-385.
Full text not available from this repository.
Official URL: http://dx.doi.org/10.1002/gcc.20541
We have investigated two patients with acquired chromosomal rearrangements, a male presenting with a t(1;9)(p34;q34) and B cell progenitor acute lymphoid leukemia and a female presenting with a t(8;12)(p11;q15) and the 8p11 myeloproliferative syndrome. We determined that the t(1;9) fused ABL to SFPQ (also known as PSF), a gene mapping to 1p34 that encodes a polypyrimidine tract-binding protein-associated splicing factor. The t(8;12) fused CPSF6, a cleavage and polyadenylation specificity factor, to FGFR1. The fusions were confirmed by amplification of the genomic breakpoints and RT-PCR. The predicted oncogenic products of these fusions, SFPQ-ABL and CPSF6-FGFR1, are in-frame and encode the N-terminal domain of the partner protein and the entire tyrosine kinase domain and C-terminal sequences of ABL and FGFR1. SFPQ interacts with two FGFR1 fusion partners, ZNF198 and CPSF6, that are functionally related to the recurrent PDGFR partner FIP1L1. Our findings thus identify a group of proteins that are important for pre-mRNA processing as fusion partners for tyrosine kinases in hematological malignancies.
|Subjects:||Technology > Medicine and Health|
|Group:||School of Health and Social Care > Centre for Postgraduate Medical Research and Education|
|Deposited By:||INVALID USER|
|Deposited On:||02 Nov 2008 15:50|
|Last Modified:||07 Mar 2013 14:51|
|Repository Staff Only -|
|BU Staff Only -|
|Help Guide -||Editing Your Items in BURO|